Newsroom

[Bloomberg] Boehringer’s New Lung Drug to Cost $96,000 a Year

Boehringer Ingelheim GmbH priced its new treatment for a deadly lung-scarring disease at $96,000 a year, just higher than Roche Holding AG’s (ROG) competing product.

Read more

[Bloomberg BNA] How Will Medicaid Plans Cover Specialty Drugs?

According to a recent survey from the Kaiser Family Foundation, almost every state Medicaid plan is concerned about the rising cost of specialty drugs — specifically Sovaldi. Sovaldi is a hepatitis c drug from Gilead Sciences which costs $1,000 a pill, or $84,000 for a 12-week treatment—prices which the plans have balked at.

Read more

Say What? Gilead Exec Compares Rx Spending to McDonald’s Prices

On the day that Gilead introduced its new $94,500 hepatitis C drug, Harvoni, Gilead Vice President of Investor Relations Patrick O’Brien went into full spin mode, telling Politico (subscription required) that Harvoni is a bargain compared to Gilead’s other hep C drug, the $84,000 Sovaldi.

Read more

[Politico Pro] The new drug war: Health lobbies spar

Harvoni’s launch brought new howls about price gouging from insurers and a broad coalition of health care groups. They warn that the drugs, no matter how revolutionary, are ultimately unaffordable given the estimated 3 million Americans who may be infected with hepatitis C.

Read more